Dr Francesca Mercuri
Academic Specialist
Department of Microbiology and Immunology
36 Scholarly works
20 Projects
HIGHLIGHTS
2026
Research contracts (non-grants)
Production of Proteins for Methanogen Vaccine Program
2025
Conference Proceedings
Safety tolerability and proof of pharmacology of a dry powder formulation of the antiviral host defense enhancer INNA-051 in healthy adults aged 18-80
DOI: 10.1183/13993003.congress-2025.pa39112025
Journal article
Priming mucosal pathogen-agnostic innate immunity with an intranasal TLR2/6 agonist in an aged population
DOI: 10.1183/23120541.01044-20242025
Journal article
Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections
DOI: 10.1016/j.antiviral.2024.1060632024
Journal article
Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology.
DOI: 10.1183/23120541.00199-20242024
Research grants (international)
Development of a Novel Long Acting Pan-Influenza Antiviral Drug
2016
Research Contracts
Testing of Anti-Influenza Compounds
RECENT SCHOLARLY WORKS
2023
Conference Proceedings
Late Breaking Abstract - INNA-051 prophylaxis enhances innate immune responses confirming accelerated viral clearnace in a human influenza challenge model.
DOI: 10.1183/13993003.congress-2023.OA24832023
Conference Proceedings
INNA-051 pre-exposure prophylaxis in a human influenza infection model
DOI: 10.1183/13993003.congress-2023.PA28232022
Conference Proceedings
SYSTEMIC ADMINISTRATION OF AXA-042, A NOVEL TLR2/6 AGONIST, RESHAPES THE TUMOR MICROENVIRONMENT, AS REVEALED BY SINGLE CELL SEQUENCING ANALYSIS
DOI: 10.1136/jitc-2022-SITC2022.11642022
Journal article
Abstract 3502: AXA-042 - a novel systemic TLR2/6 agonist for anti-tumor therapy
DOI: 10.1158/1538-7445.am2022-35022022
Conference Proceedings
AXA-042-a novel systemic TLR2/6 agonist for anti-tumor therapy
2022
Conference Proceedings
TLR2/6 Agonist Treatment Enhances Antiviral Innate Immune Responses in a Novel Mouse Coronavirus Respiratory Infection Model
DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1209
RECENT PROJECTS
2024
Research contracts (non-grants)
RNA Powered Antiviral Antibodies
2024
Research contracts (non-grants)
RNA Powered Antiviral Antibodies